ARTICLE | Emerging Company Profile
R1: China-to-U.S. NewCo planning global testing of new CKD mechanism
Via deal with China-based Alebund, the well-funded start-up is developing a therapy that could challenge phosphate binders in hyperphosphatemia
March 17, 2026 11:03 AM UTC
California-based R1 is using the NewCo model to fund global clinical testing of a molecule with first-in-class potential to treat hyperphosphatemia associated with chronic kidney disease.
Abingworth, F-Prime Capital and DaVita Venture Group have led a $77.5 million series A round for R1 Therapeutics Inc., which emerged from stealth mode early Tuesday. R1 is preparing to start a Phase IIb trial this year of lead asset AP306 (EOS789), to which it holds a license under a newly revealed deal with China-based Alebund Pharmaceuticals (Jiangsu) Ltd...